Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors



Douglas S. Paauw, MD, discussed why it’s been a bad year for antihypertensives, and provided updates on the side effects of statins and sodium-glucose cotransporter 2 inhibitors, in a video interview at the annual meeting of the American College of Physicians.

Vidyard Video

Dr. Paauw, professor of medicine at the University of Washington, Seattle, began by discussing some of the issues that occurred with antihypertensive drugs in the past year. These included the link between hydrochlorothiazide use and the increased risk of nonmelanoma skin cancers, the recalls of many drug lots of angiotensin II receptor blockers, and a study that found an increased risk of lung cancer in people who were taking ACE inhibitors.

He then described the findings of studies that examined the links between statins and muscle pain and other new research on these drugs.

He also warned physicians to be particularity cautious about prescribing sodium-glucose cotransporter 2 inhibitors to certain kinds of patients.

Dr. Paauw concluded by explaining why clarithromycin is his most hated drug.

Dr. Paauw is also the Rathmann Family Foundation Endowed Chair for Patient-Centered Clinical Education and the medicine clerkship director at the University of Washington.

Recommended Reading

Low LDL cholesterol may increase women’s risk of hemorrhagic stroke
MDedge Internal Medicine
PIONEER-HF Extension: Don’t stall starting sacubitril/valsartan
MDedge Internal Medicine
Canagliflozin lowers kidney failure risk in T2D: CREDENCE
MDedge Internal Medicine
Poor response to statins hikes risk of cardiovascular events
MDedge Internal Medicine
Dr. Joseph Vassalotti: Cancer risk minimal with ARBs
MDedge Internal Medicine